The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: Clinical course and in vivo model

Cancer

Volumn 95, Issue 8, 2002, Pages 1795-1801

  Warmann, Steven ^a,b   Hunger, Mona ^b   Teichmann, Birgit ^b   Flemming, Peer ^b   Gratz, Klaus Friedrich ^b   Fuchs, Jörg ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chemotherapy; Human hepatoblastoma; MDR1 antagonizers; P glycoprotein

Indexed keywords

ALPHA FETOPROTEIN; CISPLATIN; DOXORUBICIN; GLYCOPROTEIN P; IFOSFAMIDE; MULTIDRUG RESISTANCE PROTEIN 1; VALSPODAR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SIZE; CANCER TRANSPLANTATION; CASE REPORT; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ANALYSIS; HEPATOBLASTOMA; HUMAN; HUMAN TISSUE; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; CYCLOSPORINS; DRUG RESISTANCE, MULTIPLE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MDR; HEPATOBLASTOMA; HUMANS; INFANT; LIVER NEOPLASMS; MALE; MICE; NEOPLASMS, EXPERIMENTAL; P-GLYCOPROTEINS; TRANSPLANTATION, HETEROLOGOUS; UP-REGULATION;

EID: 0037108092     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10858     Document Type: Article

References (27)

1. King D, Ortega J, Campell J. The surgical management of children with incompletely resected hepatic cancer is facilitated by intensive chemotherapy. J Pediatr Surg. 1991;26: 1074-1981.
2. Von Schweinitz D, Hecker H, Schmidt von Arndt G, Harms D. Prognostic factors and staging system in childhood hepatoblastoma. Int J Cancer. 1997;74:1-7.
3. Von Schweinitz D, Hecker H, Harms D. Complete resection before development of drug resistance is essential for survival from advanced hepatoblastoma. J Pediatr Surg. 1995; 30:845-852.
4. Von Schweinitz D, Byrd D, Hecker H, et al. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Eur J Cancer. 1997;33: 1243-1249.
5. Bader P, Fuchs J, Wenderoth M, von Schweinitz D, Niethammer D, Beck JF. Altered expression of resistance associated genes in hepatoblastoma xenografts incorporated in mice following treatment with doxorubicin or cisplatin. Anticancer Res. 1998;18:3127-3132.
6. Minemura M, Tanimura H, Tabor E. Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines. Int J Oncol. 1999;15:559-563.
7. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multi-drug resistance gene in human cancers. J Natl Cancer Inst. 1989;81:116-124.
8. Oda Y, Röse I, Radig K, Wagemann W, Mittler U, Roessner A. Expression of MDR1/P-glycoprotein and multidrug resistance-associated protein in childhood solid tumors. Virchows Arch. 1997;430:99-105.
9. Beck J, Handgretinger R, Klingebiel T, et al. Expression of PKC isoenzyme and MDR-associated genes in primary and relapsed state AML. Leukemia. 1996;10:426-433.
10. Germann UA. P-glycoprotein-a mediator of multidrug resistance in tumor cells. Eur J Cancer. 1996;6:927-944.
11. Goldstein LJ. MDR1 gene expression in solid tumors. Eur J Cancer. 1996;6:1039-1050.
12. Fisher GA, Lum BL, Hausdorff J, Sikic BI. Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer. 1996;32:1082-1088.
13. Ferry DR, Traunecker H, Kerr DJ. Clinical trials of P-glycoprotein reversal in solid tumors. Eur J Cancer. 1996;32:1070-1081.
14. Watanabe T, Tsuge H, Oh-Hara T, Naito M, Tsuruo T. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol. 1995;2:235-241.
15. Krishna R, St-Louis M, Mayer LD. Increased intracellular drug accumulation and complete chemosensitation achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin. Int J Cancer. 2000;85:131-141.
16. Fuchs J, Bode U, von Schweinitz D, et al. Analysis of treatment efficiency of carboplatin and etoposide in combination with radical surgery in advanced and recurrent childhood hepatoblastoma: a report of the German Cooperative Pediatric Liver Tumor Study HB 89 and HB 94. Klin Pädiatr. 1999;211:305-309.
17. Beck JF, Handgretinger R, Dopfer R, et al. Expression of MDR1, MRP, topoisomerase IIα/β and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. Br J Haematol. 1995;89:356-363.
18. Fuchs J, Schmidt D, Pietsch T, et al. Successful transplantation of human hepatoblastoma into immunodeficient mice. J Pediatr Surg. 1996;31:1241-1249.
19. Fuchs J, Wenderoth M, von Schweinitz D, et al. Comparative activity of cisplatin, ifosfamide, doxorubicin, carboplatin and etoposide in heterotransplanted hepatoblastoma. Cancer. 1998;11:2400-2407.
20. Watanabe T, Naito M, Oh-hara T, Itoh Y, Cohen D, Tsuruo T. Modulation of multidrug resistance by SDZ PSC 833 in leukemic- and solid-tumor-bearing mice models. Jpn J Cancer Res. 1996;87:184-193.
21. Dawson-Saunders B, Trapp RE. Basic and clinical biostatistics. Apleton and Lange, 1994.
22. Brown J, Perilongo G, Shafford E, et al. Pretreatment prognostic factors for children with hepatoblastoma-results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer. 2000;36:1418-1425.
23. Warmann SW, Fuchs J, Wilkens L, Gratz KF, von Schweinitz D, Mildenberger H. Successful therapy of subcutaneously growing human hepatoblastoma xenografts with topotecan. Med Pediatr Oncol. 2001;37:449-454.
24. Pu YS, Hsieh TS, Tsai TC, et al. Tamoxifen enhances the chemosensitivity of bladder carcinoma cells. J Urol. 1995; 154:601-605.
25. Baekelandt M, Lehne G, Trope CG, et al. Phase I/II trial of the multidrug resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer. J Clin Oncol. 2001;19:2983-2993.
26. Watanabe T, Nakayama Y, Naito M, et al. Reversed multi-drug resistance in vitro but not in tumor-bearing mouse models. Anticancer Drugs. 1996;7:825-832.
27. Chico I, Kang MH, Bergan R, et al. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. J Clin Oncol. 2001;19:832-842.